Neuropsychiatric symptoms in people screened positive for dementia in primary care

Size: px
Start display at page:

Download "Neuropsychiatric symptoms in people screened positive for dementia in primary care"

Transcription

1 International Psychogeriatrics (2015), 27:1, C International Psychogeriatric Association 2014 doi: /s Neuropsychiatric symptoms in people screened positive for dementia in primary care... Stefan J. Teipel, 1,2 Jochen René Thyrian, 3,4 Johannes Hertel, 3 Tilly Eichler, 3 Diana Wucherer, 3 Bernhard Michalowsky, 3 Ingo Kilimann 1,2 and Wolfgang Hoffmann 3,4 1 Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany 2 DZNE, German Center for Neurodegenerative Diseases, Rostock/Greifswald, Rostock, Germany 3 DZNE, German Center for Neurodegenerative Diseases, Rostock/Greifswald, Greifswald, Germany 4 Institute for Community Medicine, University of Greifswald, Germany ABSTRACT Background: Neuropsychiatric symptoms are major determinants for caregiver distress and institutionalization in dementia. Little is known about the prevalence of neuropsychiatric symptoms and their association with use of medication, caregiver distress, and resource utilization in primary care. Methods: We assessed frequency of neuropsychiatric symptoms in a sample retrieved from a primary care intervention study. Patients were screened for dementia by their primary care physicians. A study nurse assessed neuropsychiatric symptoms in 176 patients using the neuropsychiatric inventory (NPI) through faceto-face interviews by proxy during home visits. In addition, data on global cognition (MMSE), quality of life (QoL-AD), resource utilization in dementia (RUD), caregiver distress (BIS), and use of psychotropic medication in patients were obtained. We used linear mixed effect models taking into account the clustering of patients within general physician practices. Results: Clinically relevant neuropsychiatric symptoms (NPI score 4) occurred in about 53% of the patients. Higher NPI scores were significantly associated with more severe cognitive impairment, higher caregiver distress, and higher utilization of caregiver resources by patients but not with a formal diagnosis of dementia from the primary care physician. Use of antipsychotics was associated with higher NPI scores, particularly in non-psychotic domains. Conclusions: Neuropsychiatric symptoms in a primary care cohort screened positive for dementia were associated with resource utilization and distress of caregivers. In contrast to guideline recommendations, the use of antipsychotics was associated with non-psychotic domains of behavioral symptoms. These findings underscore the relevance of neuropsychiatric symptoms for the design of future interventions in primary care. Key words: behavioral impairment, dementia, aging general practice, psychotropic medication, caregiver distress, resource utilization Introduction Dementia challenges healthcare systems worldwide (Hurd et al., 2013). Although dementia is primarily defined by cognitive disturbances, the so-called neuropsychiatric symptoms, such as wandering, night day shift, disinhibition, aggression, and agitation, are among the most distressing symptoms for caregivers of patients with dementia. The frequency and severity of neuropsychiatric symptoms are Correspondence should be addressed to: Stefan J. Teipel, MD, Department of Psychosomatic Medicine, University of Rostock, and DZNE Rostock/Greifswald, Gehlsheimer Str. 20, Rostock, Germany. Phone: ; Fax: stefan.teipel@med.uni-rostock.de. Received 12 Jun 2014; revision requested 18 Jul 2014; revised version received 30 Jul 2014; accepted 19 Aug First published online 23 September major determinants for the transition of patients from home care to institutionalized care, and have been found associated with caregiver s wellbeing and morbidity (Sansoni et al., 2013), resource utilization and cost of care (Gustavsson et al., 2011; Lacey et al., 2013), and use of psychotropic medication (Rosenberg et al., 2012). The neuropsychiatric inventory (NPI; Cummings, 1997) is among the best established instruments for the quantification of severity and frequency of neuropsychiatric symptoms. The NPI has served as primary or secondary endpoint in clinical trials and has been employed across a large range of dementia severities and nosological diagnoses. The majority of evaluations have been conducted in institutionalized care (Lai et al., 2009),

2 40 S. J. Teipel et al. specialized memory clinics (Gustavsson et al., 2010), or clinical trials (Zwijsen et al., 2014). Studies on the frequency and severity of neuropsychiatric symptoms as determined with the NPI in community dwelling people from primary care obtained during a home visit are still rare (Tatsch et al., 2006). Complementing previous evidence from institutionalized care, we aimed to determine the frequency and severity of neuropsychiatric symptoms in people screened positive for dementia living at home. We expected that in a primary care setting, increase in NPI score would be lower than in patients from specialized care as reported in the literature but similar to those obtained in community dwelling elderly patients through specialized outpatient units. As a secondary goal, we investigated potential risk factors and consequences of neuropsychiatric disturbances for both caregivers and individuals with suspected dementia in a sample from a primary care population. Data are still scarce on the prevalence, risk factors, and consequences of behavioral impairments in a primary care sample. Such data, however, will become relevant for the planning of future interventions into a healthcare system. Participants and methods Study design The present analysis was conducted as part of the study Life- and person-centered help in Mecklenburg-Western Pomerania, Germany (DelpHi-MV), a general physician (GP)-based epidemiological cohort of people above the age of 70 years who live at home (Thyrian et al., 2012). These people were screened for eligibility to participate in a trial of dementia care management. The DelpHi trial is a cluster-randomized, controlled intervention trial with two arms (intervention and control) designed to test the efficacy and efficiency of implementing a subsidiary support system for persons with dementia who live at home. General physician practices participating in the DelpHi Study screen patients aged 70 years and older in their routine care using the DemTect (Kalbe et al., 2004). In cases with DemTect < 9, indicating presence of cognitive impairment that would be indicative for dementia, the persons are eligible for the DelpHi Trial and are informed in detail about the trial and invited to participate in it. The trial has been discussed in detail and has been approved by the Ethical Committee of the Chamber of Physicians of Mecklenburg-Western Pomerania (registry number BB 20/11). There is a systematic, computer-assisted, comprehensive assessment at the participants homes, with the individual screened positive for dementia and the caregiver being interviewed face-to-face by a trained nurse. Due to cognitive limitations and the amount of information assessed, the interviewers split the assessment into at least three home visits. Participants Enrolment into the study started on 1st January 2012 and is still ongoing. By 1st January 2014, 316 participants fulfilling the inclusion criteria for the study and providing written informed consent were included. Seventy persons dropped out before the data about the inclusion criteria for the NPI were obtained (of those participants, 30 withdraw their consent, in 10 cases the holders of the durable power of attorney of the patient withdraw the consent, 23 patients had died, 3 patients had moved, 4 patients had not further specified reasons) and 63 participants were not eligible for this analysis, since they could not provide a caregiver. In the sample fulfilling the eligibility criteria for conducting the NPI, in seven patients the NPI could not be conducted for various reasons (no time, psychological burden too high on the caregiver, etc.). This yielded a final sample of 176 dyads of patients screened positive for dementia and family caregivers. Assessments The DelpHi standard assessment comprises a variety of data about socio-demographics, health status, cognitive status, activities of daily living (ADL), pharmacotherapy, utilization of services, quality of life (QoL), and caregiver burden and distress (Thyrian et al., 2012) using computerized data storage on a portable data management system (Eichler et al., 2014a). From these assessments we selected the NPI (Cummings, 1997) as our primary endpoint. The NPI represents an interview by proxy on 12 dimensions of neuropsychiatric behaviors, i.e. delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, nighttime behavior disturbances, and appetite and eating abnormalities. The severity and frequency of each neuropsychiatric symptom are rated on the basis of scripted questions administered to the patient s caregiver. A total NPI score is calculated as the product sum of the frequency by severity scores within each domain. The NPI also assesses the amount of caregiver distress engendered by each of the neuropsychiatric disorders, but the caregiver distress scores were not used in our analysis. As independent variables, we selected the Mini-Mental State Examination (MMSE) as a measure of global cognitive performance (Folstein

3 NPI in primary care 41 et al., 1975), presence of a formal diagnosis of dementia by GP (Eichler et al., 2014b), medication use as part of a comprehensive medication review (Fiss et al., 2013), and QoL as assessed with the QoL-AD score (Logsdon et al., 2002). The QoL-AD score was averaged across all 13 domains of physical health, energy, mood, living situation, memory, family, marriage, friends, self as a whole, ability to do chores around the house, and ability to do things for fun, money, and life as a whole. In addition, we used a sub-item of resource utilization in the dementia questionnaire scale (resource utilization in dementia or RUD; Wimo et al., 1998). Within the DelpHi trial we only used the sub-items of the RUD focusing on the utilization of caregiver resources by patients. Therefore, only the items on supervising the patient and assisting in instrumental activities of daily living (IADL) and ADL were assessed in the study. In the present analysis, we only used the information on assisting patients in ADL and IADL (number of days within the last 30 days and hours per day) because time of supervision could not always be assessed reliably, with some caregivers reporting more than 24 hours per day supervision. These were excluded from further analyses, leaving 150 patients with valid RUD IADL and ADL assistance items. The caregiver distress was assessed using the short version of the brief symptom inventory (BSI- 18) that assesses three dimensions, i.e. depression, anxiety, and somatization, on six items each (Derogatis and Savitz, 2000). We used the Global Severity Index (GSI) derived from the BSI-18 by averaging scores across items and dimensions. Statistics The NPI scores were binarized according to clinical relevance. NPL score 3 was considered clinically non-relevant, and NPL score 4 was considered clinically relevant (indicating a frequency of symptoms at least once a week and of moderate severity), analogous to previous studies (Lyketsos et al., 2002; Aalten et al., 2007). Analyses were conducted in the following three steps: 1. We determined potential predictors of higher NPI scores, including age, gender, and MMSE score as measures of global cognitive decline. We used a generalized mixed effects model with a logistic link function and a binomial distribution corresponding to a logistic regression using binarized NPI score as dependent variable, and GP as random effect cluster variable, where subject level observations were blocked within GPs (so that averaged NPI scores were allowed to vary between GPs). We compared the fit of this model with an extended model that included MMSE score as additional participants level random effects covariate (so that the effect of MMSE scores on NPI scores was allowed to vary between GPs). To test for overall level of significance, we used the total NPI score as binary dependent variable. If effects were significant for the binarized total NPI score, we determined follow-up models with each of the NPI subscores as dependent variables to determine the NPI subdomain that was associated with a significant overall effect. This procedure was based on the assumption that the high colinearity of NPI dimensions would render the Bonferroni correction for multiple comparisons too conservative. Age, gender, and MMSE score were forced into the model. Analyses were calculated using the procedure-generalized linear mixed models (proc glimmix) in SAS version We determined the effect of NPI score increase on patient- or caregiver-related outcomes, including RUD, QoL-AD, and total BSI scores, after controlling for MMSE score, age, and gender. These models used RUD, QoL-AD, and total BSI score respectively as continuous dependent variables, and GP as a random effect cluster variable, where subject level observations were blocked within GPs. The fit of these models was compared with the fit of extended models with additional participants level random effect covariates, as described for model (1) above. Analyses were calculated using the procedure mixed (proc mixed) in SAS version Associations between medication use and binarized NPI scores were determined using a random effects logistic regression, with medication use as independent predictor variable and the binarized total NPI score as dependent variable. Observations were blocked within GPs, which were treated as random effects variable. Analyses were calculated using proc glimmix in SAS version 9.3. For assessment of interaction with use of medication, we had a priori assumptions on expected associations of antipsychotics use with delusions and hallucinations, and antidepressants use with depression, sleep, and anxiety that were tested using multiple comparison correction with the Bonferroni Holmes method if effects survived the uncorrected threshold of p < In addition, we tested for a priori unexpected associations between antipsychotics use and the non-psychotic dimensions of the NPI score. These associations were tested at an uncorrected level of significance of p < 0.05 to control the type II error to erroneously reject an aprioriunexpected effect. Results Participants characteristics From 316 participants included into the DelpHi trial between 1st January 2012 and 1st January 2014, NPI scores were obtained for 176 patients

4 42 S. J. Teipel et al. Table 1. Participants characteristics SEX M/ F AGE MEAN ( SD), MIN MAX ( YEARS) MMSE MEDIAN (25TH AND 75TH PERCENTILE) SCHOOL EDUCATION BROKEN OFF/ 10 YEARS/ >10 YEARS/ OTHER... No formal diagnosis of dementia prior to screening Formal diagnosis of dementia prior to screening 37/ (5.12) (19 25) 8/73/8/5 35/ (5.64) (15 24) 11/57/4/7 Notes: Not different between groups, χ 2 = 0.33, 1df, p = Not different between groups, t = 0.20, 174 df, p = Significantly different between groups, Mann Whitney U test, p = Not different between groups, χ 2 = 2.8, 3df, p = 0.42; data missing from three cases. M/F: Male/female. Table 2. Total NPI score as predictor of patient- or caregiver-related outcomes AGE GENDER MMSE NPI... RUD NS NS F92 1 = 7.31, p = F92 1 = 4.19, p = BSI-18 NS NS NS F104 1 = 8.53, p = QOL-AD NS NS NS NS Notes: Statistical significance was tested using a mixed effect general linear model, with observations blocked within GP offices and total NPI score as second-level random effect covariate (see statistics section for more details), controlling for MMSE score, age, and gender. RUD: Resource utilization in dementia IADL and ADL assistance items. BSI-18: Brief symptom inventory. NS: Not significant. 104 women and 72 men. Cognitive impairment was present in all patients according to DemTect screening (a score below 9). Only 81 of the 176 patients had received a formal diagnosis of dementia from their GP. The patients receiving a formal diagnosis of dementia had no higher total NPI scores than the patients not receiving such a diagnosis after controlling for MMSE scores, age, and gender, and even if the effect of diagnosis on NPI scores was allowed to vary across GP offices (F 1 20 = 2.12, p = 0.16). Table 1 summarizes participants characteristics stratified to the presence or absence of a formal diagnosis of dementia prior to screening. Frequency of high NPI scores About 43.8% of the patients exhibited behavioral symptoms in at least one of the 12 NPI dimensions with a frequency of at least once a week and at least of moderate severity (NPI score 4). About 49% of these patients exhibited relevant behavioral symptoms in more than one dimension. Most frequently involved dimensions were apathy in 27 patients, aberrant motor behavior in 20 patients, anxiety in 18 patients, and delusions in 17 patients. About 52.8% of the participants had a total NPI score (12 items) 4(Figure 1). Association with participant s characteristics In the random effects logistic regression model, age and gender showed no significant effect on the binarized total NPI score, whereas the MMSE score showed a significant effect with an odds ratio of 0.91, F = 9.8, p < 0.003, when averaged total NPI scores were allowed to vary across GPs as random effect covariate. Follow-up tests revealed that MMSE scores were associated with delusions, hallucinations, disinhibition, aberrant motor behavior, and appetite and eating abnormalities (p < 0.05 for all comparisons). Association of NPI scores with patient- or caregiver-related outcomes Table 2 shows the effects of total NPI scores on patient- or caregiver-related outcomes. The total NPI score showed a significant association with caregiver resource utilization (combined IADL and ADL subscales of the RUD questionnaire) when averaged RUD scores were allowed to vary across GPs as random effect covariates. When we included NPI scores as a random effect covariate blocked within GPs, the fit of the model was not altered. MMSE score showed an independent contribution

5 NPI in primary care 43 Figure 1. Frequency and severity of NPI total and subdomain scores. Percentage of patients with clinically relevant increases in NPI total and subdomain scores (blue), sorted according to decreasing prevalence. NPI scores were binarized where scores more than 3 were considered clinically significant; 100% corresponds to n = 176 patients. on caregiver resource utilization subscores of the RUD questionnaire. We found a significant association of the total NPI score with caregiver distress as assessed with the BSI-18. Adding a random effects term for the total NPI score did not improve the fit of the model, suggesting that the effect of NPI scores on BSI-18 did no significantly vary across GPs. Follow-up tests revealed that the overall effect was driven by the dimensions of agitation, apathy, irritability, aberrant motor behavior, anxiety, and appetite and eating changes (p < 0.05 for all comparisons). There was no association of the total NPI score with QoL as assessed with the averaged QoL- AD questionnaire score (across all dimensions), after controlling for age, gender, and the MMSE score, neither in the random effects intercept nor the extended model with NPI score subjects level random effects covariate. Medication use Almost 66% of the patients used at least one psychotropic medication (Figure 2). Twenty-four of the 176 patients used at least one antipsychotic drug, with 20 patients using atypical and eight patients using typical antipsychotics. Twenty-seven patients used at least one antidepressant drug, with 14 of those using a tricyclic antidepressant. Eleven patients used at least one sedative drug, with five of those using benzodiazepines. Twenty-four patients used at least one antiepileptic. Seventy-four patients used at least one antidementive drug, from these 36 patients used a choline-esterase inhibitor. Association between medication use and NPI scores Overall, antipsychotics use was significantly associated with higher total NPI scores (F = 5.74, p = 0.018). Contrary to expectations, use of antipsychotics was associated with anxiety (F = 4.76, p = 0.03), apathy (F = 6.79, p = 0.01), disinhibition (F = 5.44, p = 0.02), and aberrant motor behavior (F = 13.26, p = ). In contrast, overall antipsychotics use was not significantly associated with a clinically higher NPI scores in the dimensions of hallucinations or delusions even at a not-corrected level of significance. Use of any antidepressant, sedative, antiepileptic, or antidementive drug or use of choline-esterase inhibitors was not associated with higher total NPI scores, even at an uncorrected level of significance of p < Discussion As primary endpoint of our study, we investigated the frequency and severity of neuropsychiatric

6 44 S. J. Teipel et al. Figure 2. (Colour online) Frequency distribution of use of any psychotropic medication. Percentage of cases using none, one, two, three, or four psychotropic medications respectively; 100% corresponds to n = 176 patients. symptoms using the NPI in a sample of patients screened positive for dementia in primary care during home visits. The number of patients for whom an NPI score could not be obtained during a home visit due to formal reasons, such as absence of a family caregiver, and had been excluded was relatively low (seven out of 183 eligible patients). Our data suggest that assessment of NPI scores by a trained nurse during a home visit is a feasible approach to determine severity and frequency of neuropsychiatric symptoms in an elderly primary care cohort. NPI assessments during home visits have rarely been used before. A previous population-based study in Brazil had performed assessments during home visits but only used one question from the NPI (depression), and neither reported the exact qualification of the raters ( trained mental health professionals ) nor the number of eligible patients that could not be assessed (da Silva et al., 2013). We found the highest prevalence of higher NPI scores in the domains of apathy, delusions, anxiety, and aberrant motor behavior. These domains represent three of the four components of the factor structure that has been identified to underlie the 12 items of the NPI score (Hollingworth et al., 2006), i.e. behavioral dyscontrol (including aberrant motor behavior), psychosis (including delusions), and mood (including anxiety and apathy); in contrast the component of agitation (including irritability/emotional lability and agitation/aggression) has less frequently been reported in our sample. It needs to be studied in the longitudinal course of the DelpHi trial whether a higher expression of symptoms of agitation is associated with a higher likelihood to leave the community (for example, due to institutionalization) compared with the other three domains of behavior so that our community dwelling patients would represent a negative selection in respect of symptoms of agitation. Overall, the frequency of neuropsychiatric symptoms was considerably lower than the frequency of these impairments previously reported in nursing home cohorts (for instance, Wetzels et al., 2010). This agrees with a previous longitudinal study reporting a lower prevalence of neuropsychiatric symptoms at baseline in study participants that remained living at home compared with participants that had been institutionalized

7 NPI in primary care 45 during one-year follow-up (Benoit et al., 2005). This is further consistent with the observation that more pronounced neuropsychiatric symptoms increase the likelihood of a person to enter into institutionalized care (Sansoni et al., 2013). The prevalence of higher NPI scores was lower than in previous population-based studies (Lyketsos et al., 2002; Tatsch et al., 2006), with 53% in our study and 62 to 78% in the previous studies (Lyketsos et al., 2002; Tatschet al., 2006). Several factors may account for this effect. First, one of the previous studies included patients living in nursing homes (Lyketsos et al., 2002). Second, due to the design of our primary care intervention study, we could not establish a formal diagnosis of dementia in our patients. Instead, patients were included in the DemTect based on a score of 8 or lower. There were 17 patients with an MMSE score of 28 or higher during baseline assessment in our sample, rendering the likelihood for dementia as low in these patients. Although the absence of manifest dementia does not exclude the presence of neuropsychiatric symptoms, their frequency and severity in patients without dementia, including patients with mild cognitive impairment, is lower than in patients with dementia (Lyketsos et al., 2002). In addition, one previous study counted the presence of any behavioral symptom to estimate the prevalence of behavioral impairments (Tatsch et al., 2006), thus increasing the prevalence of NPI positive participants. This contrasts with this and previous studies (Lyketsos et al., 2002; Aalten et al., 2007) that applied a cut-off before counting a reported symptom as clinically relevant. We had access to formal diagnoses of dementia from the primary care physicians. However, previous evidence suggests that primary care physicians reach a sensitivity of below 50% to reach a diagnosis of dementia (Boustani et al., 2005). Consistent with these previous data, only 46% of patients screening positive for dementia in our study carried a formal diagnosis of dementia by their GP. The frequency of clinically relevant neuropsychiatric symptoms as assessed by the total NPI score was not significantly associated with a formal diagnosis of dementia by their GP in our study, suggesting that the presence of relevant neuropsychiatric symptoms may not be a relevant driver to reach a diagnosis of dementia in primary care. As a secondary endpoint, we assessed association between higher NPI scores and patientand caregiver-related variables. Generally, lower MMSE scores were associated with higher NPI scores. This agrees with the observation from previous studies that neuropsychiatric symptoms increase with the severity of dementia (Zuidema et al., 2009). Against our expectation, NPI scores were not associated with the QoL of patients as assessed by the patients and their caregivers. Associations between QoL and NPI scores have been found in late-stage dementia in a small sample of patients (n = 31) with an atypically high prevalence of men (94%) (Benhabib et al., 2013). In mild to moderate Alzheimer s disease dementia, the NPI score was associated with proxyreported and not with self-reported ratings of QoL (Karttunen et al., 2011). This agrees with a previous study that showed an association of NPI scores at baseline with proxy-rated QoL over time, and not with self-rated change in QoL estimates (Tatsumi et al., 2009). Indeed, self- and proxy-rated estimates of QoL are only modestly associated in people with dementia (Buckley et al., 2012). Caregiverrelated variables, such as caregiver depression and burden, can strongly influence their estimates of patient s QoL (Conde-Sala et al., 2013), and may mediate the effect of neuropsychiatric symptoms on estimates of QoL. In addition, given the relatively low prevalence of neuropsychiatric symptoms in our sample, the absence of an effect does not preclude that with higher frequency and severity these symptoms become more relevant for the estimated QoL of patients with dementia. We analyzed associations between NPI scores and resource utilization and distress of the caregiver. Both NPI score and degree of cognitive impairment were independently associated with resource utilization, in agreement with the proposed important role of neuropsychiatric symptoms for cost of care in dementia (Gustavsson et al., 2011). There was a significant overall effect of the total NPI score on distress of caregivers that was driven also by less prevalent neuropsychiatric domains such as irritability and agitation. Detailed analyses of specific associations of neuropsychiatric behaviors with caregiver s psychological symptoms are still rare so that our findings require independent replication. Finally, we assessed association between medication use and NPI scores. Among all psychotropic medications, only antipsychotic use was associated with higher NPI scores. Against primary expectation that antipsychotic use would predominantly be associated with psychotic symptoms such as delusions and hallucinations, the effect was driven by aberrant motor behavior, disinhibition, apathy, and anxiety. National and international guidelines for the management of dementia as well as metaanalyses (Seitz et al., 2013) justify the use of antipsychotics only in the presence of severe psychotic symptoms and agitation. We had decided not to use the Bonferroni correction for testing associations between antipsychotics use and NPI

8 46 S. J. Teipel et al. domains that do not confirm with the guidelines. Thus, we reduced the type II error to erroneously reject the assumption that an antipsychotic use occurred against guidelines. Indeed, our findings agree with observational studies in institutionalized care that demonstrate antipsychotic medication use not only for psychotic symptoms but also for the treatment of aberrant motor behavior, disinhibition, anxiety, nighttime behavior, and irritability (Nobili et al., 2009). There are limitations associated with our study. First, due to the design of our study we could not analyze patients with a clinical diagnosis of dementia but analyzed those that were screened positive for dementia. This sets an upper limit to the number of observable symptoms, i.e. it suggests that the frequency of neuropsychiatric symptoms in a primary care cohort of patients with dementia will be at least as high as in our cohort. Second, we had decided to binarize the presence of neuropsychiatric symptoms according to a certain threshold of severity and frequency at ascore 4, similar to previous studies (Lyketsos et al., 2002). Counting every symptom as relevant even if it occurs infrequently and with mild severity appears inadequate to clinical reality where only a minimum degree of symptomatology will trigger interventions in clinical care. If we would have chosen a more conservative threshold of 5 or higher, indicating a frequency of symptoms of at least once a week and high severity, or a frequency of symptoms of at least several times a week and at least moderate severity, then the prevalence of relevant symptoms would have been even smaller but the association with other variables would have prevailed. Third, we had used items of the RUD questionnaire to assess utilization of caregiver resources by patients, focusing on IADL and ADL assistance and supervision of patients. In 26 of the 176 patients, the caregivers reported more than 24 hours per day for supervising their patient, even after further inquiry by the interviewer. This is implausible in physical time but may reflect the felt burden of caregiver. We decided to exclude entirely such cases from the analysis of RUD scores. Our data question the validity of the supervision item of the original RUD questionnaire for application in primary care samples. Indeed, a recent update of the RUD questionnaire supports the need to set an individual cap on the maximum number of hours per day and night that a caregiver should provide informal care (Wimo et al., 2013). Fourth, each single of the 12 NPI items could have been assessed in more depth using domain-specific scales such as the Hamilton or Beck s Depression Scale for depression or the Cohan Mansfield Agitation Inventory for agitation. However, in the context of a community dwelling setting with assessments being administered at individual s home by a trained nurse, the NPI has proven to be a feasible and reliable tool to comprehensively assess behavioral impairments within a reasonable timeframe. We used a generalized mixed effect model to take clustering of observations within recruiting GP practices into account. This model allowed us to flexibly integrate the effect of both GP practice on mean levels of the dependent variable and variation in the effect of patients level predictors on the outcome variable across GP practices, assuming that the GP practices of our study represented a random selection of all GP practices. One has to note that the likelihood of a given GP practice to participate in the study may have been influenced by systematic factors that would render our sample of GP practices not a truly randomly drawn selection from the entire population of GP practices. In summary, our data indicate that clinically relevant neuropsychiatric symptoms occur in 53% of the people screened positive for dementia in primary care. The prevalence of these symptoms was below that reported from nursing home samples, consistent with the notion that neuropsychiatric symptoms are a major determinant for the transition of patients from home to institutionalized care. Neuropsychiatric symptoms were associated with the severity of cognitive impairment, distress of caregivers, and utilization of caregiver resources by patients. In addition, consistent with observational clinical data, but in contrast to guideline recommendations, use of antipsychotics was predominantly associated with non-psychotic neuropsychiatric symptoms. From a clinical point of view these findings suggest that neuropsychiatric symptoms should actively be assessed in elderly patients suspected to suffer from cognitive decline. Our data indicate that this can also be reliably done in a primary care setting. Caregiver-centered interventions, such as caregiver education and support, may be the most promising approach with least side effects to treat such symptoms, given the strong association of higher NPI scores with caregiver distress and resource utilization and the discrepancy between guideline recommendations and observed medication use. The DelpHi trial is currently ongoing with a planned longitudinal follow-up over several years (Thyrian et al., 2012). Here we plan in future to determine the impact of neuropsychiatric symptoms on costs of care and clinical outcome in people screened positive for dementia as well as the impact of caregiver-based intervention on clinical outcomes of patients and caregiver distress in primary care.

9 NPI in primary care 47 Conflict of interest On behalf of all authors, the corresponding author states that there is no conflict of interest. Description of authors roles Stefan Teipel formulated the research questions, analyzed the data, and wrote the paper. Jochen René Thyrian designed and carried out the study, and was involved in drafting the paper and analyzing the data. Johannes Hertel was involved in drafting the paper and analyzing the data. Tilly Eichler and Ingo Kilimann were involved in designing and carrying out the study and drafting the paper. Diana Wucherer and Bernhard Michalowsky were involved in designing and carrying out the study. Wolfgang Hoffmann designed and carried out the study and supervised data collection. References Aalten, P. et al. (2007). Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dementia and Geriatric Cognitive Disorders, 24, Benhabib, H., Lanctot, K. L., Eryavec, G. M., Li, A. and Herrmann, N. (2013). Responsiveness of the QUALID to improved neuropsychiatric symptoms in patients with Alzheimer s disease. Canadian Geriatrics Journal, 16, Benoit, M. et al. (2005). One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer s disease. The REAL.FR Study. The Journal of Nutrition, Health & Aging, 9, Boustani, M. et al. (2005). Implementing a screening and diagnosis program for dementia in primary care. Journal of General Internal Medicine, 20, Buckley, T. et al. (2012). Predictors of quality of life ratings for persons with dementia simultaneously reported by patients and their caregivers: the Cache County (Utah) Study. International Psychogeriatrics, 24, Conde-Sala, J. L. et al. (2013). Factors associated with the variability in caregiver assessments of the capacities of patients with Alzheimer disease. Journal of Geriatric Psychiatry and Neurology, 26, Cummings, J. L. (1997). The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology, 48 (Suppl. 6), S10 S16. da Silva, S. A., Scazufca, M. and Menezes, P. R. (2013). Population impact of depression on functional disability in elderly: results from Sao Paulo Ageing & Health Study (SPAH). European Archives of Psychiatry and Clinical Neuroscience, 263, Derogatis, L. and Savitz, K. (2000). The SCL-90-R and brief symptom inventory (BSI) in primary care. In M. Maruish (ed.), Handbook of Psychological Assessment in Primary Care Settings (pp ). Mahwah, NJ: Lawrence Erlbaum. Eichler, T. et al. (2014a). The benefits of implementing a computerized Intervention-Management-System (IMS) on delivering integrated dementia care in the primary care setting. International Psychogeriatrics, 26, Eichler, T. et al. (2014b). Rates of formal diagnosis in people screened positive for dementia in primary care: results of the DelpHi-Trial. Journal of Alzheimer s Disease, 42, Fiss, T. et al. (2013). Medication management for people with dementia in primary care: description of implementation in the DelpHi study. BMC Geriatrics, 13, 121. Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). Mini-Mental-State: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, Gustavsson, A. et al. (2010). Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study. The Journal of Nutrition, Health & Aging, 14, Gustavsson, A., Cattelin, F. and Jonsson, L. (2011). Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants. Alzheimer s &Dementia, 7, Hollingworth, P. et al. (2006). Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer s disease. Journal of the American Geriatric Society, 54, Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J. and Langa, K. M. (2013). Monetary costs of dementia in the United States. New England Journal of Medicine, 368, Kalbe, E. et al. (2004). DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. International Journal of Geriatric Psychiatry, 19, Karttunen, K. et al. (2011). Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer s disease. International Journal of Geriatric Psychiatry, 26, Lacey, L. A., Niecko, T., Leibman, C., Liu, E., Grundman, M. and Group, E.-A.-I. (2013). Association between illness progression measures and total cost in Alzheimer s disease. The Journal of Nutrition, Health &Aging, 17, Lai,C.K.,Yeung,J.H.,Mok,V.andChi,I.(2009). Special care units for dementia individuals with behavioural problems. Cochrane Database of Systematic Reviews, CD Logsdon, R. G., Gibbons, L. E., McCurry, S. M. and Teri, L. (2002). Assessing quality of life in older adults with cognitive impairment. Psychosomatic Medicine, 64, Lyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J. and DeKosky, S. (2002). Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA, 288, Nobili, A. et al. (2009). Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer s special care units. International Clinical Psychopharmacology, 24,

10 48 S. J. Teipel et al. Rosenberg, P. B. et al. (2012). The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer s disease. International Journal of Geriatric Psychiatry, 27, Sansoni, J., Anderson, K. H., Varona, L. M. and Varela, G. (2013). Caregivers of Alzheimer s patients and factors influencing institutionalization of loved ones: some considerations on existing literature. Annali di Igiene: Medicina Preventiva e di Comunita, 25, Seitz, D. P. et al. (2013). Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. International Psychogeriatrics, 25, Tatsch, M. F. et al. (2006). Neuropsychiatric symptoms in Alzheimer s disease and cognitively impaired, non-demented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity. American Journal of Geriatric Psychiatry, 14, Tatsumi, H. et al. (2009). Neuropsychiatric symptoms predict change in quality of life of Alzheimer s disease patients: a two-year follow-up study. Psychiatry and Clinical Neurosciences, 63, Thyrian, J. R. et al. (2012). Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial. Trials, 13, 56. Wetzels, R. B., Zuidema, S. U., de Jonghe, J. F., Verhey, F. R. and Koopmans, R. T. (2010). Course of neuropsychiatric symptoms in residents with dementia in nursing homes over 2-year period. American Journal of Geriatric Psychiatry, 18, Wimo, A., Gustavsson, A., Jonsson, L., Winblad, B., Hsu, M. A. and Gannon, B. (2013). Application of Resource Utilization in Dementia (RUD) instrument in a global setting. Alzheimer s & Dementia, 9, e417. Wimo, A., Wetterholm, A. L., Mastey, V. and Winblad, B. (1998). Evaluation of resource utilization and caregiver time in anti-dementia drug trials a quantitative battery. In A. Wimo, B. Jonsson, G. Karlsson and B. Winblad (Eds.), The Health Economics of Dementia (pp ). London: Wiley. Zuidema, S. U., de Jonghe, J. F., Verhey, F. R. and Koopmans, R. T. (2009). Predictors of neuropsychiatric symptoms in nursing home patients: influence of gender and dementia severity. International Journal of Geriatric Psychiatry, 24, Zwijsen, S. A. et al. (2014). Coming to grips with challenging behavior: a cluster randomized controlled trial on the effects of a multidisciplinary care program for challenging behavior in dementia. Journal of the American Medical Directors Association, 15, 531 e1 e10.

Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study René Thyrian

Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study René Thyrian Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study René Thyrian German Center for Neurodegenerative Diseases (DZNE), site

More information

Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease

Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease ORIGINAL RESEARCH Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease Hadas Benhabib 1, Krista L. Lanctôt, PhD 1,2,4, Goran M. Eryavec, MD, FRCPC 3,4,

More information

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Publishing Pty Ltd593274279Original ArticleDementia and mild AlzheimersJ. Shimabukuro et al. Psychiatry and

More information

The place for treatments of associated neuropsychiatric and other symptoms

The place for treatments of associated neuropsychiatric and other symptoms The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public

More information

Reliability of the Brazilian Portuguese version of the Neuropsychiatric Inventory (NPI) for patients with Alzheimer s disease and their caregivers

Reliability of the Brazilian Portuguese version of the Neuropsychiatric Inventory (NPI) for patients with Alzheimer s disease and their caregivers International Psychogeriatrics (2008), 20:2, 383 393 C 2007 International Psychogeriatric Association doi:10.1017/s1041610207006254 Printed in the United Kingdom Reliability of the Brazilian Portuguese

More information

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Measure Description Percentage of patients with dementia for whom there was a documented screening* for behavioral

More information

The course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables

The course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry 2005; 20: 531 536. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/gps.1317 The course of neuropsychiatric

More information

Neuropsychiatric Inventory Nursing Home Version (NPI-NH)

Neuropsychiatric Inventory Nursing Home Version (NPI-NH) This is a Sample version of the Neuropsychiatric Inventory Nursing Home Version (NPI-NH) The full version of the Neuropsychiatric Inventory Nursing Home Version (NPI-NH) comes without sample watermark..

More information

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there

More information

NEUROPSYCHOMETRIC TESTS

NEUROPSYCHOMETRIC TESTS NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract

More information

Management of the Acutely Agitated Long Term Care Patient

Management of the Acutely Agitated Long Term Care Patient Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia

More information

K. Kahle-Wrobleski 1, J.S. Andrews 1, M. Belger 2, S. Gauthier 3, Y. Stern 4, D.M. Rentz 5, D. Galasko 6

K. Kahle-Wrobleski 1, J.S. Andrews 1, M. Belger 2, S. Gauthier 3, Y. Stern 4, D.M. Rentz 5, D. Galasko 6 The Journal of Prevention of Alzheimer s Disease - JPAD Volume 2, Number 2, 2015 Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimer s Disease: Transforming Functional

More information

Severity and prevalence of behavioral and psychological symptoms among patients of different dementia stages in Taiwan

Severity and prevalence of behavioral and psychological symptoms among patients of different dementia stages in Taiwan Original article Severity and prevalence of behavioral and psychological symptoms among patients of different dementia stages in Taiwan Si-Sheng Huang 1, Wen-Fu Wang 2, Yi-Cheng Liao 1 1 Department of

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Atri A, Frölich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on in cognition in patients with Alzheimer disease: three randomized clinical

More information

Range of neuropsychiatric disturbances in patients with Parkinson s disease

Range of neuropsychiatric disturbances in patients with Parkinson s disease 492 Section of Geriatric Psychiatry, Rogaland Psychiatric Hospital D Aarsland N G Lim C Janvin Department of Neurology, Central Hospital of Rogaland, Stavanger, Norway J P Larsen K Karlsen E Tandberg Departments

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #283: Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences

More information

Research Article Sex Differences in Neuropsychiatric Symptoms of Alzheimer s Disease: The Modifying Effect of Apolipoprotein E ε4 Status

Research Article Sex Differences in Neuropsychiatric Symptoms of Alzheimer s Disease: The Modifying Effect of Apolipoprotein E ε4 Status Behavioural Neurology Volume 2015, Article ID 275256, 6 pages http://dx.doi.org/10.1155/2015/275256 Research Article Sex Differences in Neuropsychiatric Symptoms of Alzheimer s Disease: The Modifying Effect

More information

Psychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic

Psychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic Original Articles 179 Psychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic Ching-Sen Shih 1, Sui-Hing Yan 2, Ying-Hoo Ho 1, Yuh-Te Lin 1, Jie-Yuan Li 1, and Yuk-Keung Lo 1 Abstract-

More information

Dysphoric symptoms in relation to other behavioral and psychological symptoms of dementia, among elderly in nursing homes

Dysphoric symptoms in relation to other behavioral and psychological symptoms of dementia, among elderly in nursing homes Lindbo et al. BMC Geriatrics (2017) 17:206 DOI 10.1186/s12877-017-0603-4 RESEARCH ARTICLE Open Access Dysphoric symptoms in relation to other behavioral and psychological symptoms of dementia, among elderly

More information

Number of Items. Response Categories. Part V: Specific Behavior Scales-Sleep Scales. Based on past month

Number of Items. Response Categories. Part V: Specific Behavior Scales-Sleep Scales. Based on past month Part V: Specific Behavior Scales-Sleep Scales Based on past month First 4 items ask for time or amount of sleep 41. Pittsburgh Sleep Quality Index (PSQI) Sleep quality Sleep latency Sleep duration Habitual

More information

Measuring health-related quality of life in persons with dementia DOMS results & recommendations

Measuring health-related quality of life in persons with dementia DOMS results & recommendations Measuring health-related quality of life in persons with dementia DOMS results & recommendations Madeleine King, Siggi Zapart, Jan Sansoni, Nick Marosszeky On behalf of the Dementia Outcomes Measurement

More information

CLUSTERING OF BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA (BPSD): A EUROPEAN ALZHEIMER S DISEASE IN CONSORTIUM (EADC) STUDY

CLUSTERING OF BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA (BPSD): A EUROPEAN ALZHEIMER S DISEASE IN CONSORTIUM (EADC) STUDY 426 Original articles CLUSTERING OF BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA (BPSD): A EUROPEAN ALZHEIMER S DISEASE IN CONSORTIUM (EADC) STUDY M. Petrovic 1,2, C. Hurt 2, D. Collins 2, A. Burns

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized controlled trial. JAMA. doi:10.1001/jama.2014.93 eappendix.

More information

DEMENTIA MEASURES GROUP OVERVIEW

DEMENTIA MEASURES GROUP OVERVIEW DEMENTIA MEASURES GROUP OVERVIEW 2015 PQRS OPTIONS F MEASURES GROUPS: 2015 PQRS MEASURES IN DEMENTIA MEASURES GROUP: #47 Care Plan #280 Dementia: Staging of Dementia #281 Dementia: Cognitive Assessment

More information

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top

More information

NeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M.

NeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. ISSNISSN ISSN: 2456-3927 NeuroPharmac Journal Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. Alshahrani www. neuropharmac.com Jan-April 2018, Volume 3, Issue

More information

Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care

Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia

More information

CHCS. Multimorbidity Pattern Analyses and Clinical Opportunities: Dementia. Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES

CHCS. Multimorbidity Pattern Analyses and Clinical Opportunities: Dementia. Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES CHCS Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES Multimorbidity Pattern Analyses and Clinical Opportunities: Dementia December 2010 Cynthia Boyd, MD, MPH* Bruce Leff, MD* Carlos

More information

The Neuropsychiatric Inventory Questionnaire: Background and Administration

The Neuropsychiatric Inventory Questionnaire: Background and Administration The Neuropsychiatric Inventory Questionnaire: Background and Administration The Neuropsychiatric Inventory Questionnaire (NPI-Q) was developed and crossvalidated with the standard NPI to provide a brief

More information

Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia

Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia 86 Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia Pai-Yi Chiu 1,3, Chung-Hsiang Liu 2, and Chon-Haw Tsai 2 Abstract- Background: Neuropsychiatric profile

More information

A pan-european study on outcome measures for psychosocial intervention research in dementia

A pan-european study on outcome measures for psychosocial intervention research in dementia A pan-european study on outcome measures for psychosocial intervention research in dementia CHATTAT Rabih, MONIZ-COOK Esme, WOODS Bob, and members of the INTERDEM JPND outcomes working group 26 th Alzheimer

More information

NIH Public Access Author Manuscript Dement Geriatr Cogn Disord. Author manuscript; available in PMC 2013 August 28.

NIH Public Access Author Manuscript Dement Geriatr Cogn Disord. Author manuscript; available in PMC 2013 August 28. NIH Public Access Author Manuscript Published in final edited form as: Dement Geriatr Cogn Disord. 2012 ; 34(2): 96 111. doi:10.1159/000342119. Neuropsychiatric symptoms and global functional impairment

More information

Research Article Behavioural and Psychological Symptoms in Poststroke Vascular Cognitive Impairment

Research Article Behavioural and Psychological Symptoms in Poststroke Vascular Cognitive Impairment Behavioural Neurology, Article ID 430128, 5 pages http://dx.doi.org/10.1155/2014/430128 Research Article Behavioural and Psychological Symptoms in Poststroke Vascular Cognitive Impairment Meena Gupta,

More information

American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline

American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline I. Geriatric Psychiatry Patient Care and Procedural Skills Core Competencies A. Geriatric psychiatrists shall

More information

Measuring health related quality of life in persons with dementia

Measuring health related quality of life in persons with dementia University of Wollongong Research Online Australian Health Services Research Institute Faculty of Business 2008 Measuring health related quality of life in persons with dementia Madeleine King University

More information

Torstein F. Habiger, 1 Elisabeth Flo, 1 Wilco P. Achterberg, 2 and Bettina S. Husebo 1,3. 1. Introduction

Torstein F. Habiger, 1 Elisabeth Flo, 1 Wilco P. Achterberg, 2 and Bettina S. Husebo 1,3. 1. Introduction Behavioural Neurology Volume 16, Article ID 7361, 8 pages http://dx.doi.org/1.11/16/7361 Clinical Study The Interactive Relationship between Pain, Psychosis, and Agitation in People with Dementia: Results

More information

White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration

White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration Annual Scientific Meeting Canadian Geriatric Society Philippe Desmarais,

More information

QUESTIONNAIRE: Finland

QUESTIONNAIRE: Finland QUESTIONNAIRE: Finland To put the assessment and management of behavioural disorders into a broader context of social and health policy and services in Finland, some background information is presented.

More information

The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-topay

The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-topay The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-topay approach Wu G, Lanctot K L, Herrmann N, Moosa S, Oh P I Record Status This is a critical abstract of an economic

More information

Validation of apathy evaluation scale and assessment of severity of apathy in Alzheimer s diseasepcn_

Validation of apathy evaluation scale and assessment of severity of apathy in Alzheimer s diseasepcn_ Psychiatry and Clinical Neurosciences 2012; 66: 227 234 doi:10.1111/j.1440-1819.2011.02315.x Regular Article Validation of apathy evaluation scale and assessment of severity of apathy in Alzheimer s diseasepcn_2315

More information

BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA

BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological

More information

City, University of London Institutional Repository

City, University of London Institutional Repository City Research Online City, University of London Institutional Repository Citation: Hurt, C. S., Banerjee, S., Tunnard, C., Whitehead, D. L., Tsolaki, M., Mecocci, P., Kloszewska, I., Soininen, H., Vellas,

More information

Psychosis and Agitation in Dementia

Psychosis and Agitation in Dementia Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University

More information

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer

More information

Depression in the elderly community: I. Prevalence by different diagnostic criteria and clinical profile

Depression in the elderly community: I. Prevalence by different diagnostic criteria and clinical profile Eur. J. Psychiat. Vol. 22, N. 3, (131-140) 2008 Keywords: Depression, Elderly, Prevalence, Psychopathology, Epidemiology Depression in the elderly community: I. Prevalence by different diagnostic criteria

More information

Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms. l The diagnosis of AD l Neuropsychiatric symptoms l Place of the ICT

Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms. l The diagnosis of AD l Neuropsychiatric symptoms l Place of the ICT Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms State of the art lecture March 4-2012 Philippe H Robert, Philippe Nice - France Robert The diagnosis of AD Neuropsychiatric

More information

LTC Research Influencing Practice

LTC Research Influencing Practice LTC Research Influencing Practice David A. Nace, MD, MPH Division of Geriatric Medicine naceda@upmc.edu PGS Clinical Update April 6, 2017 Conflicts of Interest Dr. Nace does not have any current conflicts

More information

Dementia is a common neuropsychiatric disorder characterized by progressive impairment of

Dementia is a common neuropsychiatric disorder characterized by progressive impairment of Focused Issue of This Month Diagnosis and Treatment for Behavioral and Psychological Symptoms of Dementia Byoung Hoon Oh, MD Department of Psychiatry, Yonsei University College of Medicine E - mail : drobh@yuhs.ac

More information

Psychological therapies for people with dementia who have associated depression [New 2015].

Psychological therapies for people with dementia who have associated depression [New 2015]. Psychological therapies for people with dementia who have associated depression [New 2015]. SCOPING QUESTION: For people with dementia and comorbid depression, do psychological interventions (including

More information

Behavioural disturbances in dementia patients and quality of the marital relationship

Behavioural disturbances in dementia patients and quality of the marital relationship INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry 2003; 18: 149 154. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/gps.807 Behavioural disturbances

More information

Irene Røen 1*, Geir Selbæk 1,2,3, Øyvind Kirkevold 1,2,4, Knut Engedal 2, Ingelin Testad 5 and Sverre Bergh 1,2

Irene Røen 1*, Geir Selbæk 1,2,3, Øyvind Kirkevold 1,2,4, Knut Engedal 2, Ingelin Testad 5 and Sverre Bergh 1,2 Røen et al. BMC Health Services Research (2017) 17:365 DOI 10.1186/s12913-017-2289-x RESEARCH ARTICLE Resource Use and Disease Course in dementia - Nursing Home (REDIC-NH), a longitudinal cohort study;

More information

Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit

Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Problem: For dementia patients, antipsychotic medications are prescribed

More information

Behavioural Problems and Patterns of Psychopharmacological Treatment given in Elderly Patients with Dementia

Behavioural Problems and Patterns of Psychopharmacological Treatment given in Elderly Patients with Dementia The International Journal of Indian Psychology ISSN 2348-5396 (e) ISSN: 2349-3429 (p) Volume 6, Issue 4, DIP: 18.01.090/20180604 DOI: 10.25215/0604.090 http://www.ijip.in October-December, 2018 Research

More information

Pharmacological Treatment of Aggression in the Elderly

Pharmacological Treatment of Aggression in the Elderly Pharmacological Treatment of Aggression in the Elderly Howard Fenn, MD Adjunct Clinical Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University Self-Assessment Question

More information

DEMENTIA MEASURES GROUP OVERVIEW

DEMENTIA MEASURES GROUP OVERVIEW 2016 PQRS OPTIONS F MEASURES GROUPS: DEMENTIA MEASURES GROUP OVERVIEW 2016 PQRS MEASURES IN DEMENTIA MEASURES GROUP: #47 Care Plan #134 Preventive Care and Screening: Screening for Clinical Depression

More information

SYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)

SYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY) SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,

More information

Recognition and Management of Behavioral Disturbances in Dementia

Recognition and Management of Behavioral Disturbances in Dementia Recognition and Management of Behavioral Disturbances in Dementia Danielle Hansen, DO, MS (Med Ed), MHSA INTRODUCTION 80% 90% of patients with dementia develop at least one behavioral disturbances or psychotic

More information

Rational Medication Use in Dementia

Rational Medication Use in Dementia Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this

More information

DEMENTIA MEASURES GROUP OVERVIEW

DEMENTIA MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: DEMENTIA MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DEMENTIA MEASURES GROUP: #280. Dementia: Staging of Dementia #281. Dementia: Cognitive Assessment #282. Dementia:

More information

Gerardo Machnicki 1, Ricardo F. Allegri 1,2 *, Carol Dillon 1, Cecilia M. Serrano 1,2 and Fernando E Taragano 2 SUMMARY INTRODUCTION

Gerardo Machnicki 1, Ricardo F. Allegri 1,2 *, Carol Dillon 1, Cecilia M. Serrano 1,2 and Fernando E Taragano 2 SUMMARY INTRODUCTION INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry (2008) Published online in Wiley InterScience (www.interscience.wiley.com).2133 Cognitive, functional and behavioral factors associated

More information

Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4

Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4 Management of Agitation in Dementia Kimberly Triplett Ferguson, MS4 Objectives 1. Review recommended evaluation of agitated patients with dementia. 2. Discuss evidence concerning nonpharmacologic management.

More information

Introduction. original article. Camilla Callegari Ivano Caselli Marta Ielmini Simone Vender E-bPC

Introduction. original article. Camilla Callegari Ivano Caselli Marta Ielmini Simone Vender E-bPC original article Camilla Callegari Ivano Caselli Marta Ielmini Simone Vender Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Insubria, Varese, Italy Influence of

More information

Neuropsychiatric Syndromes

Neuropsychiatric Syndromes Neuropsychiatric Syndromes Susan Czapiewski,MD VAHCS December 10, 2015 Dr. Czapiewski has indicated no potential conflict of interest to this presentation. She does intend to discuss the off-label use

More information

Reference. 9. Nobili, A., Piana, I., Balossi, L., Pasina, L., Matucci, M., Tarantola, M.,... Tettamanti,

Reference. 9. Nobili, A., Piana, I., Balossi, L., Pasina, L., Matucci, M., Tarantola, M.,... Tettamanti, Dementia care mode The concept of dementia specialized care unit was developed in America in the seventies, in the aim to provide better care to people with dementia. There are no concrete standards on

More information

Known as both a thief and murderer,

Known as both a thief and murderer, &A Dementia Drugs: When Should They Be Stopped? Ron Keren, MD, FRCPC As presented at the University of Toronto s Primary Care Conference, Toronto, Ontario (May 25) Known as both a thief and murderer, Alzheimer

More information

Quality ID #282: Dementia: Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care

Quality ID #282: Dementia: Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care Quality ID #282: Dementia: Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:

More information

Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary

Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease Summary Mai 17 th 2017 Background Alzheimer s disease is a serious neurocognitive disorder which is characterized

More information

An#psycho#c Medica#on in People with Demen#a

An#psycho#c Medica#on in People with Demen#a An#psycho#c Medica#on in People with Demen#a GERARD BYRNE BSc (Med), MBBS (Hons), PhD, FRANZCP, MFPOA School of Medicine, University of Queensland Mental Health Service, Royal Brisbane & Women s Hospital

More information

MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA

MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA Dr. Dallas Seitz MD PhD FRCPC Associate Professor and Division Chair, Division of Geriatric Psychiatry Department of Psychiatry, Queen s University President,

More information

Kingston Caregiver Stress Scale

Kingston Caregiver Stress Scale Kingston Caregiver Stress Scale ADMINISTRATION AND INTERPRETATION MANUAL Seniors Mental Health Program, Providence Care Mental Health Services Kingston, Canada K7L 4X3 The Kingston Scales and Manuals can

More information

Clinical Characteristics of Behavioral and Psychological Symptoms in Patients with Drug-naïve Alzheimer s Disease

Clinical Characteristics of Behavioral and Psychological Symptoms in Patients with Drug-naïve Alzheimer s Disease Dementia and Neurocognitive Disorders 2012; 11: 87-94 ORIGINAL ARTICLE Clinical Characteristics of Behavioral and Psychological Symptoms in Patients with Drug-naïve Alzheimer s Disease Yong Tae Kwak, M.D.,

More information

Screening Summary (SS2)

Screening Summary (SS2) 15Screening SummarySS217 Aug 06 Depression in Alzheimer s Disease Study - 2 DIADS-2 Screening Summary (SS2) Keyed: ( ) Purpose: Document findings about eligibility for DIADS-2 and about medical and social

More information

Introduction to Dementia: Complications

Introduction to Dementia: Complications Introduction to Dementia: Complications Created in March 2005 Duration: about 15 minutes Axel Juan, MD The Geriatrics Institute axel.juan@med.va.gov 305-575-3388 Credits Principal medical contributor:

More information

Assessing and Treating Agitation Associated with Alzheimer s Disease

Assessing and Treating Agitation Associated with Alzheimer s Disease AXS-05 R&D Day April 24, 2018 Assessing and Treating Agitation Associated with Alzheimer s Disease Marc E. Agronin, MD VP, Behavioral Health and Clinical Research, Miami Jewish Health Affiliate Associate

More information

Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches

Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize

More information

Psychological factors that influence fall risk: implications for prevention

Psychological factors that influence fall risk: implications for prevention Psychological factors that influence fall risk: implications for prevention Kaarin J. Anstey Professor & Director, Ageing Research Unit, Centre for Mental Health Research Psychological perspective on Injury

More information

Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia

Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia STEER 2002; Vol 2: No.2 Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia Bunmi Fajemisin Evidence search date: November 2001 www.signpoststeer.org

More information

Rates of formal diagnosis of dementia in primary care: The effect of screening

Rates of formal diagnosis of dementia in primary care: The effect of screening Alzheimer s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 87 93 Cognitive & Behavioral Assessment Rates of formal diagnosis of dementia in primary care: The effect of screening Tilly

More information

Mental and Behavioral Disturbances in Dementia: Findings from the Cache County Study on Memory in Aging

Mental and Behavioral Disturbances in Dementia: Findings from the Cache County Study on Memory in Aging Utah State University DigitalCommons@USU Psychology Faculty Publications Psychology 2000 Mental and Behavioral Disturbances in : Findings from the Cache County Study on Memory in Aging Constantine G. Lyketsos

More information

Clinical Study Depressive Symptom Clusters and Neuropsychological Performance in Mild Alzheimer s and Cognitively Normal Elderly

Clinical Study Depressive Symptom Clusters and Neuropsychological Performance in Mild Alzheimer s and Cognitively Normal Elderly Hindawi Publishing Corporation Depression Research and Treatment Volume 2011, Article ID 396958, 6 pages doi:10.1155/2011/396958 Clinical Study Depressive Symptom Clusters and Neuropsychological Performance

More information

PREVALENCE AND CORRELATES OF ANXIETY IN ALZHEIMER S DISEASE

PREVALENCE AND CORRELATES OF ANXIETY IN ALZHEIMER S DISEASE 166 Chemerinski et al. DEPRESSION AND ANXIETY 7:166 170 (1998) PREVALENCE AND CORRELATES OF ANXIETY IN ALZHEIMER S DISEASE Erán Chemerinski, M.D., 1 * Gustavo Petracca, M.D., 1 Facundo Manes, M.D., 2 Ramón

More information

Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials

Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimer s & Dementia 4 (2008) 390 394 Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Donald J. Connor a, *, Marwan N. Sabbagh a, Jeffery L. Cummings b a Cleo

More information

GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT

GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

Assessment and management of behavioral and psychological symptoms of dementia

Assessment and management of behavioral and psychological symptoms of dementia Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,

More information

INFORMAL CARE COST AND OUT-OF-POCKET PAYMENT TO SUPPORT PEOPLE WITH DEMENTIA: THEIR MICRO-LEVEL DETERMINANTS IN A LARGE

INFORMAL CARE COST AND OUT-OF-POCKET PAYMENT TO SUPPORT PEOPLE WITH DEMENTIA: THEIR MICRO-LEVEL DETERMINANTS IN A LARGE + INFORMAL CARE COST AND OUT-OF-POCKET PAYMENT TO SUPPORT PEOPLE WITH DEMENTIA: THEIR MICRO-LEVEL DETERMINANTS IN A LARGE SAMPLE SURVEY IN JAPAN Takayo Nakabe 1, Noriko Sasaki 1, Hironori Uematsu 1, Susumu

More information

Parkinsonian Disorders with Dementia

Parkinsonian Disorders with Dementia Parkinsonian Disorders with Dementia George Tadros Consultant in Old Age Liaison Psychiatry, RAID, Heartlands Hospital Professor of Dementia and Liaison Psychiatry, Aston Medical School Aston University

More information

Antipsychotic Medications

Antipsychotic Medications TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood

More information

Title. CitationAustralasian Journal on Ageing, 31(3): Issue Date Doc URL. Rights. Type. File Information

Title. CitationAustralasian Journal on Ageing, 31(3): Issue Date Doc URL. Rights. Type. File Information Title Randomised controlled pilot study in Japan comparing with a home visit with conversation alone Ukawa, Shigekazu; Yuasa, Motoyuki; Ikeno, Tamiko; Yo Author(s) Kishi, Reiko CitationAustralasian Journal

More information

BDNF Variants Influence Educational Attainment But Not Disease Characteristics in Alzheimers Disease

BDNF Variants Influence Educational Attainment But Not Disease Characteristics in Alzheimers Disease Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 7-9-2009 BDNF Variants Influence Educational Attainment But Not Disease

More information

A 36-month follow-up of decline in activities of daily living in individuals receiving domiciliary care

A 36-month follow-up of decline in activities of daily living in individuals receiving domiciliary care Helvik et al. BMC Geriatrics (2015) 15:47 DOI 10.1186/s12877-015-0047-7 RESEARCH ARTICLE Open Access A 36-month follow-up of decline in activities of daily living in individuals receiving domiciliary care

More information

Anosognosia, or loss of insight into one s cognitive

Anosognosia, or loss of insight into one s cognitive REGULAR ARTICLES Anosognosia Is a Significant Predictor of Apathy in Alzheimer s Disease Sergio E. Starkstein, M.D., Ph.D. Simone Brockman, M.A. David Bruce, M.D. Gustavo Petracca, M.D. Anosognosia and

More information

A wide range of neuropsychiatric disturbances commonly

A wide range of neuropsychiatric disturbances commonly 36 PAPER Neuropsychiatric symptoms in patients with Parkinson s disease and dementia: frequency, profile and associated care giver stress D Aarsland, K Brønnick, U Ehrt, P P De Deyn, S Tekin, M Emre, J

More information

Dementia: Rethinking our approach to behaviour

Dementia: Rethinking our approach to behaviour Dementia: Rethinking our approach to behaviour Dr Kathryn Lord Research Fellow 1 A bit about me: The 3 P s! Psychology Psychiatry Person centredcare 2 Challenging behaviours in Challenging behaviours dementia

More information

N europsychiatric symptoms can induce marked disability

N europsychiatric symptoms can induce marked disability PAPER Neuropsychiatric profiles in patients with Alzheimer s disease and vascular dementia J-L Fuh, S-J Wang, J L Cummings... See end of article for authors affiliations... Correspondence to: Dr J-L Fuh,

More information

CRITICAL ANALYSIS PROBLEMS

CRITICAL ANALYSIS PROBLEMS CRITICAL ANALYSIS PROBLEMS MOCK EXAMINATION Paper II 2015 STIMULUS THIS STIMULUS IS NOT TO BE REMOVED FROM THE EXAMINATION ROOM DIRECTIONS To be used as a handout while answering questions. Do not answer

More information

CORRECTED COPY Department of Veterans Affairs VHA DIRECTIVE Veterans Health Administration Washington, DC December 9, 2010

CORRECTED COPY Department of Veterans Affairs VHA DIRECTIVE Veterans Health Administration Washington, DC December 9, 2010 CORRECTED COPY Department of Veterans Affairs VHA DIRECTIVE 2010-054 Veterans Health Administration Washington, DC 20420 CATASTROPHICALLY DISABLED VETERAN EVALUATION, ENROLLMENT, AND CERTAIN COPAYMENT-EXEMPTIONS

More information

Across the Spectrum of Dementia. Keys to Understanding Behaviours & Anticipating Needs

Across the Spectrum of Dementia. Keys to Understanding Behaviours & Anticipating Needs Across the Spectrum of Dementia Keys to Understanding Behaviours & Anticipating Needs Outline Review current predictions for dementia prevalence, & the implications for future needs Discuss retrogenesis

More information

Professor Tony Holland, Department of Psychiatry, University of Cambridge

Professor Tony Holland, Department of Psychiatry, University of Cambridge INFORMATION SHEET The Use of Medication for Challenging Behaviour Professor Tony Holland, Department of Psychiatry, University of Cambridge Introduction Challenging behaviours displayed by people with

More information